Texas Pharmacy Shut Out of Controlled Substances by DEA
Published Date: 4/1/2025
Notice
Summary
Baijes Bissonnet Pharmacy in Texas tried to get a DEA registration but got denied because they filled risky prescriptions without fixing warning signs. They missed the deadline to ask for a hearing, so the DEA’s decision stands. This means the pharmacy can’t legally handle certain controlled medicines, affecting their business and customers right away.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Baijes Bissonnet Pharmacy Registration Denied
Baijes Bissonnet Pharmacy's application for a DEA Certificate of Registration (Control No. W22147152A) is denied. The denial is effective May 1, 2025, and the Order also denies any other pending DEA registration application by Baijes Bissonnet Pharmacy in Texas.
Patients Lose Controlled-Med Access At Pharmacy
Customers who rely on Baijes Bissonnet Pharmacy in Stafford, Texas may no longer be able to obtain controlled-substance prescriptions there after May 1, 2025 because the pharmacy's DEA registration application was denied. The Order follows findings that the pharmacy repeatedly filled controlled-substance prescriptions with multiple red flags from at least March 2021 through August 2022.
Filling Red-Flag Prescriptions Risks Registration
The DEA found that repeatedly filling controlled-substance prescriptions that contained red flags (for example: pattern prescribing, cash payments, long-distance patients, and drug ‘cocktails’) supports denial of DEA registration. The Agency relied on factual findings including that 492 of 575 controlled-substance prescriptions (85%) were paid in cash and that 42 prescriptions to six individuals were essentially identical.
Missing Hearing Deadline Can Cause Default
The DEA deemed the applicant in default because it did not file a timely hearing request after being served the Order to Show Cause on December 19, 2023; the 30-day deadline for a hearing request ran to January 18, 2024. A default is deemed a waiver of the right to a hearing and an admission of the OSC allegations, which supported the Agency's request for final action.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-05526, Phong H. Tran, M.D.; Decision and Order
The DEA has officially denied Dr. Phong H. Tran’s application to register for handling controlled substances in California because he’s excluded from federal health programs and lacks state permission. This means Dr. Tran can’t legally prescribe or manage certain drugs, impacting his medical practice and patients. The decision is final as of April 1, 2025, and no appeals were filed.
Next: 2025-05528, Mary Massullo, D.O.; Decision and Order
Mary Massullo, D.O., lost her license to handle controlled substances because she no longer has permission from Ohio, where she’s registered. She didn’t ask for a hearing, so the DEA decided to revoke her registration officially. This means she can’t legally work with controlled drugs anymore, and her registration expired on January 31, 2025.